Literature DB >> 2302550

3,4-Dihydroxyphenylacetic acid concentrations in the intermediate lobe and neural lobe of the posterior pituitary gland as an index of tuberohypophysial dopaminergic neuronal activity.

S E Lindley1, J W Gunnet, K J Lookingland, K E Moore.   

Abstract

Tuberohypophysial dopamine (DA) neurons terminate in the intermediate and neural lobes of the posterior pituitary. The objective of this study was to determine if concentrations of 3,4-dihydroxyphenylacetic acid (DOPAC), a major metabolite of DA in these regions, reflect the activity of tuberohypophysial DA neurons. The concentrations of DOPAC and DA in the intermediate lobe were approximately twice those in the neural lobe, so that the ratios of DOPAC/DA were similar between lobes. The administration of a monoamine oxidase inhibitor pargyline produced a rapid decline (by 5 min) of DOPAC concentrations in both the intermediate and neural lobes. The administration of nomifensine, an inhibitor of DA uptake at the nerve terminal, produced a modest 33% decline in DOPAC concentrations in the intermediate lobe, but was without effect in the neural lobe. Activation of tuberohypophysial DA neurons by electrical stimulation of the pituitary stalk increased both the rate of DA synthesis (accumulation of dihydroxyphenylalanine (DOPA) after administration of the decarboxylase inhibitor NSD 1015) and the concentrations of DOPAC in the intermediate and neural lobes. Administration of the DA antagonist haloperidol increased, and the DA agonist apomorphine decreased both the rate of DOPA accumulation and DOPAC concentrations in the intermediate lobe but not the neural lobe. The results of the present study demonstrate that: (1) elimination of DOPAC from the intermediate lobe and neural lobe is rapid and alterations in DOPAC concentrations reflect dynamic changes in metabolism of DA; (2) DA which is released and recaptured is a minor contributor to DOPAC concentrations; and (3) alterations in the activity of tuberohypophysial DA neurons are accompanied by corresponding changes in DOPAC concentrations.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2302550     DOI: 10.1016/0006-8993(90)91209-y

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  11 in total

1.  Neonatal androgen-dependent sex differences in lumbar spinal cord dopamine concentrations and the number of A11 diencephalospinal dopamine neurons.

Authors:  Samuel S Pappas; Chelsea T Tiernan; Bahareh Behrouz; Cynthia L Jordan; S Marc Breedlove; John L Goudreau; Keith J Lookingland
Journal:  J Comp Neurol       Date:  2010-07-01       Impact factor: 3.215

2.  Anatomical and functional characterization of clock gene expression in neuroendocrine dopaminergic neurons.

Authors:  Michael T Sellix; Marcel Egli; Maristela O Poletini; De'Nise T McKee; Matthew D Bosworth; Cheryl A Fitch; Marc E Freeman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2005-12-22       Impact factor: 3.619

3.  Comparison of the structure, function and autophagic maintenance of mitochondria in nigrostriatal and tuberoinfundibular dopamine neurons.

Authors:  Hae-Young Hawong; Joseph R Patterson; Brittany M Winner; John L Goudreau; Keith J Lookingland
Journal:  Brain Res       Date:  2015-07-02       Impact factor: 3.252

4.  Opioid-mediated regulation of A11 diencephalospinal dopamine neurons: pharmacological evidence of activation by morphine.

Authors:  Samuel S Pappas; Tom Kennedy; John L Goudreau; Keith J Lookingland
Journal:  Neuropharmacology       Date:  2011-05-13       Impact factor: 5.250

5.  Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice.

Authors:  H L Melrose; J C Dächsel; B Behrouz; S J Lincoln; M Yue; K M Hinkle; C B Kent; E Korvatska; J P Taylor; L Witten; Y-Q Liang; J E Beevers; M Boules; B N Dugger; V A Serna; A Gaukhman; X Yu; M Castanedes-Casey; A T Braithwaite; S Ogholikhan; N Yu; D Bass; G Tyndall; G D Schellenberg; D W Dickson; C Janus; M J Farrer
Journal:  Neurobiol Dis       Date:  2010-07-24       Impact factor: 5.996

6.  Liquid chromatographic-electrospray mass spectrometric determination of 1-methyl-4-phenylpyridine (MPP+) in discrete regions of murine brain.

Authors:  Andreas Lehner; Margaret Johnson; Tyrell Simkins; Kelly Janis; Keith Lookingland; John Goudreau; Wilson Rumbeiha
Journal:  Toxicol Mech Methods       Date:  2010-12-13       Impact factor: 2.987

7.  Estradiol and song affect female zebra finch behavior independent of dopamine in the striatum.

Authors:  Lace A Svec; Keith J Lookingland; Juli Wade
Journal:  Physiol Behav       Date:  2009-07-15

8.  Enhanced humoral immunity in mice lacking CB1 and CB2 receptors (Cnr1-/-/Cnr2-/- mice) is not due to increased splenic noradrenergic neuronal activity.

Authors:  Tyrell Simkins; Robert B Crawford; John L Goudreau; Keith J Lookingland; Barbara L F Kaplan
Journal:  J Neuroimmune Pharmacol       Date:  2014-05-29       Impact factor: 4.147

9.  Unique responses to mitochondrial complex I inhibition in tuberoinfundibular dopamine neurons may impart resistance to toxic insult.

Authors:  B Behrouz; R E Drolet; Z A Sayed; K J Lookingland; J L Goudreau
Journal:  Neuroscience       Date:  2007-06-20       Impact factor: 3.590

10.  Reduced Noradrenergic Signaling in the Spleen Capsule in the Absence of CB1 and CB2 Cannabinoid Receptors.

Authors:  Tyrell J Simkins; David Fried; Kevin Parikh; James J Galligan; John L Goudreau; Keith J Lookingland; Barbara L F Kaplan
Journal:  J Neuroimmune Pharmacol       Date:  2016-06-10       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.